Skip to main navigation Skip to search Skip to main content

Retinitis pigmentosa GTPase regulator‑related retinopathy and gene therapy

  • Nida Wongchaisuwat
  • , Alessia Amato
  • , Andrew E. Lamborn
  • , Paul Yang
  • , Lesley Everett
  • , Mark E. Pennesi
  • Oregon Health & Science University

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Retinitis pigmentosa GTPase regulator (RPGR)‑related retinopathy is a retinal dystrophy inherited in a X‑linked recessive manner that typically causes progressive visual loss starting in childhood with severe visual impairment by the fourth decade of life. It manifests as an early onset and severe form of retinitis pigmentosa. There are currently no effective treatments for RPGR‑related retinopathy; however, there are multiple clinical trials in progress exploring gene augmentation therapy aimed at slowing down or halting the progression of disease and possibly restoring visual function. This review focuses on the molecular biology, clinical manifestations, and the recent progress of gene therapy clinical trials.

Original languageEnglish
Pages (from-to)276-286
Number of pages11
JournalSaudi Journal of Ophthalmology
Volume37
Issue number4
DOIs
Publication statusPublished - 1 Oct 2023

Keywords

  • Gene therapy
  • X‑linked retinitis pigmentosa
  • retinitis pigmentosa GTPase regulator

Fingerprint

Dive into the research topics of 'Retinitis pigmentosa GTPase regulator‑related retinopathy and gene therapy'. Together they form a unique fingerprint.

Cite this